title: [Histone deacetylase inhibitor MS-275 treatment alters immune molecule content and categories in hepatocarcinoma exosomes].
abstract: OBJECTIVE
  To investigate the effects of the histone deacetylase inhibitor, MS-275, on the immune molecule content and categories in hepatocarcinoma exosomes.
  
  
  METHODS
  Exosomes were isolated from the human hepatocarcinoma cell lines, HepG2 and Hep3b, and purified by a combination technique of ultrafiltration centrifugation and sucrose gradient ultracentrifugation. The expressions of heat shock protein (HSP)70, human leukocyte antigen (HLA)-I, HLA-DR, cluster of differentiation (CD) 80 and NY-ESO-1 on exosomes were analyzed with immunoelectron microscopy and Western blotting before and after MS-275 treatment. Intergroup differences were statistically analyzed by the Student's paired t-test.
  
  
  RESULTS
  MS-275 treatment of both HepG2 and Hep3b cell types significantly increased the numbers of exosomes, their total protein content, and expression of HSP70, HLA-I and CD80 (per 100 exosomes), as compared to non-treated cells (all, P less than 0.01). MS-275 was also found to induce de novo expression of HLA-DR, but had no significant effect on NY-ESO-1 expression (P more than 0.05). The findings from immunoelectron microscopy confirmed those from Western blotting.
  
  
  CONCLUSIONS
  The histone deacetylase inhibitor, MS-275, can significantly alter the immune molecule content and categories in exosomes of hepatocarcinoma cells. The differential expression profile may reflect an anti-cancer immune response and represent molecular targets for novel anti-hepatoma therapeutic or preventative strategies.
authors.affiliation: Department of Oncology, the First Affiliated Hospital, Chinese PLA General Hospital, Beijing 100048, China.
authors.forename: Qiu-wen
authors.initials: QW
authors.lastname: Li
authors.forename: Wen-hua
authors.initials: WH
authors.lastname: Xiao
authors.forename: Gaowa
authors.initials: G
authors.lastname: Sarengaowa
authors.forename: Wei-wei
authors.initials: WW
authors.lastname: Dong
authors.forename: Hui-xia
authors.initials: HX
authors.lastname: Zhao
authors.forename: Xin-yu
authors.initials: XY
authors.lastname: Duan
authors.forename: Jian-hua
authors.initials: JH
authors.lastname: Zhu
authors.forename: Huan-rong
authors.initials: HR
authors.lastname: Kang
authors.forename: Yan
authors.initials: Y
authors.lastname: Fu
authors.forename: Yi-xin
authors.initials: YX
authors.lastname: Hao
authors.forename: Ru-liang
authors.initials: RL
authors.lastname: Wang
authors.forename: Lin-ping
authors.initials: LP
authors.lastname: Song
authors.forename: Ming
authors.initials: M
authors.lastname: Ye
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology / Q000378:metabolism; D001549:Benzamides / Q000494:pharmacology*; D006528:Carcinoma, Hepatocellular / Q000276:immunology / Q000378:metabolism*; D055354:Exosomes / Q000276:immunology / Q000378:metabolism*; D056945:Hep G2 Cells; D015395:Histocompatibility Antigens Class I / Q000276:immunology / Q000378:metabolism; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology*; D006801:Humans; D011725:Pyridines / Q000494:pharmacology*
chemical_list: D000951:Antigens, Neoplasm; D001549:Benzamides; D015395:Histocompatibility Antigens Class I; D056572:Histone Deacetylase Inhibitors; D011725:Pyridines; C118739:entinostat